This is a routine leadership transition with a planned handoff. No immediate trading catalyst. Monitor for any changes in pipeline execution or strategic direction under the new CSO.
Price Chart
Executive Summary
Perspective Therapeutics announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer, succeeding co-founder Michael K. Schultz, Ph.D., who transitions to Senior Scientific Advisor & Co-Founder as part of a planned retirement transition. Dr. Lyne brings over 25 years of oncology research experience, most recently leading Merck KGaA's global oncology research organization. This is a routine leadership change with no material financial impact.
Key Facts
- Paul Lyne, Ph.D., appointed Chief Science Officer, effective immediately.
- Michael K. Schultz, Ph.D., co-founder and former CSO, transitions to Senior Scientific Advisor & Co-Founder as part of a planned retirement.
- Dr. Lyne previously served as SVP and Head of Oncology Research at Merck KGaA, with over 25 years of industry experience.
- Perspective Therapeutics is a radiopharmaceutical development company focused on alpha-emitting 212Pb-based cancer therapies.
Financial Impact
No direct financial impact; leadership transition is organizational.
Risk Factors
- Key personnel transition risk as CSO role changes hands.
- Potential disruption to pipeline execution during the transition period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3323922 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.09 (−32.32%) |
Oct 8, 2026 19d ago | 8-K | $2.71 | awaiting T+20 | — | $1.09 (−59.79%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.09 (−60.52%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.09 (−62.68%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.09 (−61.22%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.09 (−63.56%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.09 (−65.08%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.09 (−65.08%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.09 (−65.74%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.09 (−63.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers